Shannon, A.H.; Ruff, S.M.; Schenk, A.D.; Washburn, K.; Pawlik, T.M. Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies. Medicina2023, 59, 1290.
Shannon, A.H.; Ruff, S.M.; Schenk, A.D.; Washburn, K.; Pawlik, T.M. Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies. Medicina 2023, 59, 1290.
Shannon, A.H.; Ruff, S.M.; Schenk, A.D.; Washburn, K.; Pawlik, T.M. Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies. Medicina2023, 59, 1290.
Shannon, A.H.; Ruff, S.M.; Schenk, A.D.; Washburn, K.; Pawlik, T.M. Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies. Medicina 2023, 59, 1290.
Abstract
Transplant oncology is a relatively new field in which transplantation is used to treat patients who would otherwise be unresectable. New anticancer treatment paradigms using tumor and transplant immunology and cancer immunogenomics are emerging. In turn, liver transplantation (LT) has become a potential therapy for certain patients with colorectal cancer (CRC) with liver metastasis, hepatocellular (HCC), cholangiocarcinoma (CCA), and metastatic neuroendocrine tumor (NET) to the liver. Although there are established criteria for LT in HCC, the evidence regarding LT as a treatment modality for certain gastrointestinal malignancies is still debated. The aim of this review is to highlight updates in the role of LT for certain malignancies, including HCC, metastatic CRC, hilar CCA, and neuroendocrine tumor (NET), as well as contextualize LT use and discuss controversies in transplant oncology.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
